Sugi Predict

Sugi Predict / Compounds / SCHEMBL2268486

SCHEMBL2268486

SCHEMBL2268486

CC(=O)N[C@@H](C=O)Cc1ccc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CAPN1 P07384 3/20 0.58
▸ TACR1 P25103 1/20 0.53
▸ ACACB O00763 1/20 0.51
▸ MMP9 P14780 2/20 0.47
▸ MMP8 P22894 2/20 0.47
▸ HTR2A P28223 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ HTR2B P41595 1/20 0.46
▸ MME P08473 2/20 0.45
▸ ACE P12821 2/20 0.45
▸ CPA1 P15085 2/20 0.45
▸ ACE2 Q9BYF1 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ PSMB5 P28074 1/20 0.44
▸ CTSL P07711 1/20 0.42
▸ CTSB P07858 1/20 0.42
▸ CTSS P25774 1/20 0.42
▸ CTSK P43235 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2265964 1.00 CAPN1 (0.58) CAPN1TACR1ACACBMMP9MMP8
SCHEMBL2545520 0.87 CAPN1 (0.62) CAPN1TACR1MMP9MMP8HTR2A
SCHEMBL9630720 0.82 CAPN1 (0.53) CAPN1MMP9MMP8HTR2AHTR2C
SCHEMBL15203070 0.82 CAPN1 (0.53) CAPN1MMP9MMP8HTR2AHTR2C
SCHEMBL26180350 0.82 CAPN1 (0.53) CAPN1MMP9MMP8HTR2AHTR2C
SCHEMBL5997552 0.82 CTSK (0.60) CAPN1TACR1ACECTSLCTSB
SCHEMBL7299695 0.82 CTSK (0.60) CAPN1TACR1ACECTSLCTSB
SCHEMBL7645794 0.82 CTSK (0.60) CAPN1TACR1ACECTSLCTSB
SCHEMBL2269431 0.82 CAPN1 (0.58) CAPN1ACECTSB
SCHEMBL5563236 0.82 CAPN1 (0.58) CAPN1ACECTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195898-A1 TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS VOYAGER PHARMACEUTICAL CORPORATION (US) 2011-08-11 — — US claimed
US-20080171736-A1 Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists VOYAGER PHARMACEUTICAL CORPORATION 2008-07-17 — — US claimed
EP-0683792-B1 LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 ABBOTT LAB (US) 2001-09-26 — — EP claimed
EP-0673254-A4 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS. ABBOTT LAB (US) 1998-11-18 — — EP claimed
EP-0683792-A4 LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. ABBOTT LAB (US) 1998-11-18 — — EP claimed
US-5698522-A INHIBIT RELEASE OF LUTEINIZING HORMONE RELEASING HORMONE ABBOTT LABORATORIES (US) 1997-12-16 — — US claimed
JP-H08505611-A — — 1996-06-18 — — JP claimed
JP-H08504209-A — — 1996-05-07 — — JP claimed
EP-0683792-A1 LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 ABBOTT LABORATORIES (US) 1995-11-29 — — EP claimed
EP-0673254-A1 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 1995-09-27 — — EP claimed
WO-1994014841-A1 LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 ABBOTT LABORATORIES (US) 1994-07-07 — — WO claimed
WO-1994013313-A1 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 1994-06-23 — — WO claimed
EP-0400065-A4 LHRH ANALOGS — 1991-03-13 — — EP claimed
EP-0413209-A1 LHRH analogs TAP Pharmaceuticals Inc. (US) 1991-02-20 — — EP claimed
EP-0400065-A1 LHRH ANALOGS. ABBOTT LAB (US) 1990-12-05 — — EP claimed
WO-1989007450-A1 LHRH ANALOGS ABBOTT LABORATORIES (US) 1989-08-24 — — WO claimed
EP-0328090-A2 LHRH analogs ABBOTT LABORATORIES (US) 1989-08-16 — — EP claimed
US-20110195898-A1 TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS VOYAGER PHARMACEUTICAL CORPORATION (US) 2011-08-11 — — US disclosed
WO-1989007450-A1 LHRH ANALOGS ABBOTT LABORATORIES (US) 1989-08-24 — — WO disclosed
EP-0328090-A2 LHRH analogs ABBOTT LABORATORIES (US) 1989-08-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195898-A1 TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS GNRHR, GRIN1, GRIN3A CAPN1 1240/4885TACR1 227/4885ACACB 806/4885
US-20080171736-A1 Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists GNRHR, GRIN1, GRIN3A CAPN1 1240/4885TACR1 227/4885ACACB 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.